Analysts expect Teva Pharma Industries to report Q1 2026 revenue of $3.87 billion and non-GAAP EPS of $0.55, with the stock currently priced at $36.10, roughly 14% below the average analyst target of $41.78.
The central focus for investors remains the commercial performance of Teva’s innovative trio—Austedo, Ajovy, and Uzedy—which is critical to the company's "Pivot to Growth" strategy.
Markets are looking for these high-margin brands to sufficiently offset the significant revenue erosion in the generics business, particularly from intensifying Revlimid competition in the United States. Investor sentiment has been further buoyed by the company’s recent $700 million acquisition of Emalex Biosciences and a consistent string of earnings beats throughout the prior fiscal year.